Research results continue to confirm the positive benefit-risk profile of belimumab (Benlysta®), finding that the treatment does not significantly raise the risk of safety concerns compared to a placebo drug. These findings are consistent with previously reported data, making belimumab one of the most studied lupus treatments for safety.

In the latest study, findings from six different clinical trials were pooled and analyzed. All together, the analysis included data from a diverse population of 4,170 adults with lupus treated with either belimumab or a placebo in addition to standard therapy over 52 weeks. After comparing safety outcomes between the two groups, researchers found overall occurrence of health complications, regardless of the level of seriousness or severity, and mortality rates were similar between the two treatment groups. No new concerns were identified.

In 2011, belimumab became the first FDA-approved medication specifically designed for the treatment of lupus, and the latest findings add to the growing body of evidence demonstrating its safety. Learn about belimumab: what you need to know.

Read the study